GlobeNewswire: Establishment Labs Holdings Inc Contains the last 10 of 77 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T13:52:40ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2020/12/14/2144446/0/en/Motiva-Ergonomix2-Platform-and-Motiva-Mia-Implant-Receive-CE-Mark.html?f=22&fvtc=4&fvtv=35474Motiva Ergonomix2 Platform and Motiva Mia Implant Receive CE Mark2020-12-14T13:00:00Z<![CDATA[SANTA BARBARA, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced it has received a CE mark for its next generation Motiva Ergonomix2® silicone breast implant platform. The CE mark also includes the Motiva Ergonomix2 Diamond® breast implant, which is the implant that will be used in the Motiva Mia® minimally invasive breast augmentation system when it is approved.]]>https://www.globenewswire.com/news-release/2020/12/10/2143033/0/en/Establishment-Labs-Completes-21-Motiva-Mia-Patients-in-IRB-Approved-Study-in-Costa-Rica.html?f=22&fvtc=4&fvtv=35474Establishment Labs Completes 21 Motiva Mia Patients in IRB Approved Study in Costa Rica2020-12-10T13:00:00Z<![CDATA[SANTA BARBARA, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced it recently received Institutional Review Board (IRB) approval to initiate a patient series in Costa Rica to study its Motiva Mia® system for minimally invasive augmentation, which includes the Motiva Ergonomix2 Diamond® breast implant, and has completed the procedure in the first 21 patients in the study.]]>https://www.globenewswire.com/news-release/2020/11/10/2123743/0/en/Establishment-Labs-to-Participate-in-Two-Upcoming-Investment-Conferences.html?f=22&fvtc=4&fvtv=35474Establishment Labs to Participate in Two Upcoming Investment Conferences2020-11-10T13:00:00Z<![CDATA[SANTA BARBARA, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced its participation in two investment conferences this month.]]>https://www.globenewswire.com/news-release/2020/11/09/2123171/0/en/Establishment-Labs-Reports-Third-Quarter-2020-Financial-Results.html?f=22&fvtc=4&fvtv=35474Establishment Labs Reports Third Quarter 2020 Financial Results2020-11-09T21:05:00Z<![CDATA[SANTA BARBARA, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced its financial results for the third quarter ended September 30, 2020.]]>https://www.globenewswire.com/news-release/2020/10/21/2111813/0/en/Establishment-Labs-Reports-Preliminary-Third-Quarter-Revenue-and-Cash-Balance.html?f=22&fvtc=4&fvtv=35474 Establishment Labs Reports Preliminary Third Quarter Revenue and Cash Balance2020-10-21T12:00:00Z<![CDATA[SANTA BARBARA, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today reported strong preliminary revenue and cash figures for the quarter ended September 30, 2020.]]>https://www.globenewswire.com/news-release/2020/10/21/2111824/0/en/Establishment-Labs-Celebrates-10-Years-of-Motiva-Safety-Data.html?f=22&fvtc=4&fvtv=35474Establishment Labs Celebrates 10 Years of Motiva Safety Data2020-10-21T12:00:00Z<![CDATA[SANTA BARBARA, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, is today announcing its latest clinical data demonstrating 10 years of outstanding safety outcomes reported in women who have received the Company’s Motiva® silicone breast implants.]]>https://www.globenewswire.com/news-release/2020/10/07/2105235/0/en/Establishment-Labs-to-Celebrate-10-Years-of-Motiva-Safety-Data-at-Plastic-Surgeon-Virtual-Symposium.html?f=22&fvtc=4&fvtv=35474Establishment Labs to Celebrate 10 Years of Motiva Safety Data at Plastic Surgeon Virtual Symposium2020-10-07T20:45:45Z<![CDATA[Event to Feature Members of Company’s Medical and Scientific Advisory Boards and U.S. IDE Medical Director Event to Feature Members of Company’s Medical and Scientific Advisory Boards and U.S. IDE Medical Director]]>https://www.globenewswire.com/news-release/2020/09/25/2099302/0/en/Establishment-Labs-Finalizes-Distribution-Agreement-with-Puregraft-LLC.html?f=22&fvtc=4&fvtv=35474Establishment Labs Finalizes Distribution Agreement with Puregraft LLC2020-09-25T13:00:00Z<![CDATA[SANTA BARBARA, Calif., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced it has finalized an amendment to its distribution agreement with Puregraft LLC for Puregraft’s line of products for autologous adipose tissue harvesting and redistribution. This amended agreement, which now will continue through the end of 2022, modifies the terms of the original distribution agreement that had terminated earlier this year.]]>https://www.globenewswire.com/news-release/2020/09/21/2096465/0/en/Establishment-Labs-Announces-Independent-Publication-Detailing-New-Advancements-in-Hybrid-Breast-Reconstruction-Technique-Using-Motiva-Ergonomix-Implants.html?f=22&fvtc=4&fvtv=35474Establishment Labs Announces Independent Publication Detailing New Advancements in Hybrid Breast Reconstruction Technique Using Motiva Ergonomix Implants2020-09-21T12:00:00Z<![CDATA[SANTA BARBARA, Calif., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, announced today that a recently published independent study concluded that the hybrid breast reconstruction approach using Motiva® Ergonomix implants improved outcomes in implant-based breast reconstructions.]]>https://www.globenewswire.com/news-release/2020/09/02/2087641/0/en/ESTA-Announces-Participation-in-the-Wells-Fargo-Virtual-Healthcare-Conference.html?f=22&fvtc=4&fvtv=35474ESTA Announces Participation in the Wells Fargo Virtual Healthcare Conference2020-09-02T12:00:00Z<![CDATA[NEW YORK, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced that CEO and Founder Juan José Chacón-Quirós and Chief Financial Officer Renee Gaeta will participate in the 2020 Wells Fargo Virtual Healthcare Conference, which is being held September 9-10, 2020. Mr. Chacón-Quirós and Ms. Gaeta are scheduled to speak to conference attendees at 2:00 pm ET on Wednesday, September 9, 2020.]]>